Table 5.
Correlation analyses of DAGLβ expression with clinical pathophysiological parameters in patients with ICC
| Characteristics | Number of Patients |
P Value | |
|---|---|---|---|
| Low DAGLβ expression | High DAGLβ expression | ||
| Gender | 0.45 | ||
| Male | 27 | 23 | |
| Female | 17 | 20 | |
| Age | 0.91 | ||
| ≤57 | 22 | 21 | |
| >57 | 22 | 22 | |
| Hepatolithiasis | 0.03 | ||
| Negative | 34 | 24 | |
| Positive | 10 | 19 | |
| Primary sclerosing cholangitis | >0.99 | ||
| Negative | 43 | 42 | |
| Positive | 1 | 1 | |
| HBsAg | 0.22 | ||
| Negative | 32 | 26 | |
| Positive | 12 | 17 | |
| HBcAb | 0.06 | ||
| Negative | 31 | 22 | |
| Positive | 13 | 21 | |
| CA19-9 | 0.09 | ||
| ≤35 U/L | 21 | 13 | |
| >35 U/L | 23 | 30 | |
| CEA | 0.00 | ||
| ≤5 μg/L | 32 | 18 | |
| >5 μg/L | 12 | 25 | |
| Tumor size | 0.00 | ||
| ≤5 cm | 25 | 12 | |
| >5 cm | 19 | 31 | |
| Tumor differentiation | 0.59 | ||
| <Moderate | 20 | 22 | |
| ≥Moderate | 24 | 21 | |
| Number of tumor | 0.86 | ||
| Single | 31 | 31 | |
| Multiple | 13 | 12 | |
| Lymph node metastasis | 0.05 | ||
| Negative | 34 | 25 | |
| Positive | 10 | 18 | |
| AJCC 8th TNM stage | 0.01 | ||
| I/II | 30 | 18 | |
| III/IV | 14 | 25 | |
DAGLβ, diacylglycerol lipase β; ICC, intrahepatic cholangiocarcinoma. Bold letters represented P values < 0.05.